Short Interest in Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Drops By 97.7%

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the recipient of a significant decline in short interest in May. As of May 15th, there was short interest totaling 18,505 shares, a decline of 97.7% from the April 30th total of 802,992 shares. Based on an average daily trading volume, of 318,127 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.0% of the shares of the stock are sold short.

Provectus Biopharmaceuticals Price Performance

Shares of PVCT stock traded down $0.00 during mid-day trading on Wednesday, hitting $0.06. The company had a trading volume of 463,345 shares, compared to its average volume of 160,444. Provectus Biopharmaceuticals has a 52-week low of $0.04 and a 52-week high of $0.11. The stock’s 50 day moving average price is $0.06 and its 200-day moving average price is $0.06.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc is a U.S.-based clinical-stage biopharmaceutical company focused on the development and commercialization of immuno-oncology and tumor ablation therapies. Headquartered in Knoxville, Tennessee, the company’s lead investigational product is PV-10, a proprietary formulation of Rose Bengal disodium for intralesional injection. PV-10 is designed to selectively ablate tumor cells while stimulating a systemic immune response against cancerous lesions.

PV-10 has been evaluated in multiple clinical trials across a range of solid tumors, with key studies conducted in melanoma, hepatocellular carcinoma and other refractory cancers.